胰岛素类似物安全性研究进展

Safety profile of insulin analogues

胰岛素类似物可模拟人体胰岛素生理分泌,提供更为灵活的用药时间,降低低血糖风险,现被视为大具前景的理想药物。但由于其改变了正常胰岛素的分子结构,亦可能带来某些安全方面的隐患。本文从以下4个方面探讨胰岛素类似物的安全性:低血糖事件的发生率,胰岛素作用于胰岛素样生长因子-1受体的潜在危害,过敏反应和妊娠患者的使用。一般认为,短效胰岛素类似物相对安全,glargine尚需要进一步的研究证据,慎用于儿童与妊娠妇女。

Novel insulin analogues that afford more flexible treatment regimens with a lower risk of hypoglycemia are thought of promising ＇designer drugs＇ since they simulate physiological insulin profiles. But the safety concern comes with the profit becanse of the alteration of molecular structure. The safety profile mainly includes： the frequency of hypoglycemia, adverse effect resulted from the increased binding affinity of insulin-like growth factor-1 receptor, drug allergy and the use in pregnant women. Generally speaking, rapidly acting analogues are con- sidered relatively safe, while glargine should be used with caution for children and pregnant women because the safety concern needs more data.